2. >>Products
  3. >>Biosimilars

Competition Intensifies As Access Increases For US Biosimilars

AmerisourceBergen’s Beth McMahon Also Highlights Ranibizumab And Adalimumab Rivals

 
• By Dave Wallace

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.

Five Paper Planes Colours
US biosimilars “will likely go from an average of three competitors to probably upwards of five in every single one of the existing therapeutic markets” • Source: Shutterstock

With new ground continuing to be broken in US biosimilars – including most recently the launch of the first rival to Lucentis (ranibizumab) by Samsung Bioepis and Biogen – the industry is expecting even bigger things to come in 2023, as the arrival of multi-source competition to Humira (adalimumab) grows ever closer.

In an exclusive interview, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy, Beth McMahon, speaks to Generics Bulletin about what is on the horizon for US biosimilars industry stakeholders, including a fresh wave of new players entering the market that is set to both increase

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products